Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer.

Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S.

Mol Cancer Ther. 2018 Nov 6. pii: molcanther.0584.2018. doi: 10.1158/1535-7163.MCT-18-0584. [Epub ahead of print]

PMID:
30401696
2.

Detection of the T cell activation state using non-linear optical microscopy.

Gavgiotaki E, Filippidis G, Zerva I, Kenanakis G, Archontakis E, Agelaki S, Georgoulias V, Athanassakis I.

J Biophotonics. 2018 Oct 23:e201800277. doi: 10.1002/jbio.201800277. [Epub ahead of print]

PMID:
30353667
3.

Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.

Papadaki C, Stratigos M, Markakis G, Spiliotaki M, Mastrostamatis G, Nikolaou C, Mavroudis D, Agelaki S.

Breast Cancer Res. 2018 Jul 11;20(1):72. doi: 10.1186/s13058-018-1001-3.

4.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

5.

Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes.

Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S.

Mol Oncol. 2018 Jan;12(1):21-32. doi: 10.1002/1878-0261.12114. Epub 2017 Nov 16.

6.

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.

Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V.

Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22.

7.

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.

Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A.

Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.

8.

Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.

Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G.

Oncotarget. 2017 Jan 17;8(3):5309-5322. doi: 10.18632/oncotarget.14144.

9.

Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.

Matikas A, Syrigos KN, Agelaki S.

Clin Lung Cancer. 2016 Nov;17(6):507-516. doi: 10.1016/j.cllc.2016.05.021. Epub 2016 Jun 8. Review.

PMID:
27373516
10.

Distinction between breast cancer cell subtypes using third harmonic generation microscopy.

Gavgiotaki E, Filippidis G, Markomanolaki H, Kenanakis G, Agelaki S, Georgoulias V, Athanassakis I.

J Biophotonics. 2017 Sep;10(9):1152-1162. doi: 10.1002/jbio.201600173. Epub 2016 Oct 18.

PMID:
27753229
11.

The promise of immunotherapy in head and neck squamous cell carcinoma.

Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A.

Ann Oncol. 2016 Sep;27(9):1675-85. doi: 10.1093/annonc/mdw226. Epub 2016 Jul 5. Review.

PMID:
27380958
12.

Recurrent Cerebellar Desmoplastic/Nodular Medulloblastoma in Cerebrospinal Fluid (CSF) in the Elderly. A Cytologic Diagnosis.

Kalogeraki A, Tamiolakis D, Mavrigiannaki P, Karvelaskalogerakis M, Datseri G, Agelaki S, Papadopoulos S.

Rom J Intern Med. 2016 Apr-Jun;54(2):137-9. doi: 10.1515/rjim-2016-0018.

PMID:
27352444
13.

A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.

Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S.

Cancer Chemother Pharmacol. 2016 May;77(5):949-56. doi: 10.1007/s00280-016-2997-7. Epub 2016 Mar 19.

PMID:
26994909
14.

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients.

Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V.

Breast Cancer Res. 2015 Aug 19;17:113. doi: 10.1186/s13058-015-0624-x.

15.

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.

Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V.

PLoS One. 2015 Jun 17;10(6):e0123683. doi: 10.1371/journal.pone.0123683. eCollection 2015.

16.

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer.

Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, Georgoulias V, Theodoropoulos PA.

BMC Cancer. 2015 May 13;15:399. doi: 10.1186/s12885-015-1386-7.

17.

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2015 Apr;75(4):821-7. doi: 10.1007/s00280-015-2707-x. Epub 2015 Feb 22.

PMID:
25702051
18.

Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).

Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V.

Lung Cancer. 2015 Apr;88(1):57-62. doi: 10.1016/j.lungcan.2015.01.012. Epub 2015 Jan 23.

PMID:
25662596
19.

ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V.

Cancer Invest. 2015 Apr;33(4):107-13. doi: 10.3109/07357907.2014.1001897. Epub 2015 Feb 3.

PMID:
25647444
20.

Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy.

Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K, Georgoulias V, Agelaki S.

Breast Cancer Res. 2014 Nov 29;16(6):485. doi: 10.1186/s13058-014-0485-8.

21.

Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.

Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2015 Jan;75(1):153-60. doi: 10.1007/s00280-014-2628-0. Epub 2014 Nov 15.

PMID:
25398698
22.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26.

PMID:
25344760
23.

Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer.

Papadaki MA, Kallergi G, Zafeiriou Z, Manouras L, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S.

BMC Cancer. 2014 Sep 3;14:651. doi: 10.1186/1471-2407-14-651.

24.

Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.

Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E, Mavroudis D.

Clin Breast Cancer. 2014 Dec;14(6):442-50. doi: 10.1016/j.clbc.2014.04.001. Epub 2014 Jun 2.

PMID:
24958324
25.

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

Bidard FC, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga JY, Michiels S.

Lancet Oncol. 2014 Apr;15(4):406-14. doi: 10.1016/S1470-2045(14)70069-5. Epub 2014 Mar 11.

PMID:
24636208
26.

Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.

Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2014 Apr;73(4):685-93. doi: 10.1007/s00280-014-2387-y. Epub 2014 Feb 4.

PMID:
24493157
27.

Apoptotic circulating tumor cells in early and metastatic breast cancer patients.

Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulias V, Agelaki S.

Mol Cancer Ther. 2013 Sep;12(9):1886-95. doi: 10.1158/1535-7163.MCT-12-1167. Epub 2013 Jun 18.

28.

Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.

Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V.

Cancer. 2013 Aug 1;119(15):2754-64. doi: 10.1002/cncr.28132. Epub 2013 May 9.

29.

A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.

Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V.

Cancer Chemother Pharmacol. 2013 Jul;72(1):45-51. doi: 10.1007/s00280-013-2167-0. Epub 2013 Apr 21.

PMID:
23604531
30.

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.

Vlachostergios PJ, Gioulbasanis I, Ghosh S, Tsatsanis C, Papatsibas G, Xyrafas A, Hatzidaki E, Vasiliou C, Kamposioras K, Agelaki S, Margioris AN, Nasi D, Georgoulias V, Papandreou CN.

Clin Transl Oncol. 2013 Nov;15(11):903-9. doi: 10.1007/s12094-013-1021-5. Epub 2013 Mar 5.

PMID:
23463594
31.

A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group.

Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N, Vardakis N, Rovithi M, Georgoulias V, Agelaki S.

J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.

PMID:
23433445
32.

Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.

Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.

Cancer Chemother Pharmacol. 2013 Mar;71(3):605-12. doi: 10.1007/s00280-012-2037-1. Epub 2013 Jan 22.

PMID:
23338050
33.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17.

34.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.

Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V.

Br J Cancer. 2012 Jun 5;106(12):1917-25. doi: 10.1038/bjc.2012.202.

35.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D.

Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29.

PMID:
22377561
36.

Familial mesothelioma in first degree relatives.

Kalogeraki AM, Tamiolakis DJ, Lagoudaki ED, Papadakis MN, Papadakis GZ, Agelaki SI, Stathopoulos EN, Tzardi MN.

Diagn Cytopathol. 2013 Jul;41(7):654-7. doi: 10.1002/dc.21859. Epub 2012 Feb 20.

PMID:
22351650
37.

A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V.

Clin Lung Cancer. 2012 Mar;13(2):129-35. doi: 10.1016/j.cllc.2011.08.004. Epub 2011 Oct 14.

PMID:
22000696
38.

Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer.

Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D.

J BUON. 2011 Apr-Jun;16(2):215-8.

PMID:
21766488
39.

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D.

Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897.

40.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S.

Breast Cancer Res. 2011 Jun 10;13(3):R59. doi: 10.1186/bcr2896.

41.

Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.

Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S.

Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11.

PMID:
21550556
42.

Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect.

Spiliotaki M, Markomanolaki H, Mela M, Mavroudis D, Georgoulias V, Agelaki S.

Lung Cancer. 2011 Aug;73(2):158-65. doi: 10.1016/j.lungcan.2010.11.010. Epub 2010 Dec 28.

PMID:
21190751
43.

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.

Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V.

BMC Cancer. 2010 Nov 19;10:633. doi: 10.1186/1471-2407-10-633.

44.

A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.

Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V.

Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11.

PMID:
21069335
45.

A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.

Kotsakis A, Hatzidaki D, Vamvakas L, Vardakis N, Kalykaki A, Bozionelou V, Androulakis N, Kalbakis K, Saridaki Z, Georgoulias V, Agelaki S.

Anticancer Res. 2010 Oct;30(10):4335-42.

PMID:
21036760
46.

What's new on circulating tumor cells? A meeting report.

Lianidou ES, Mavroudis D, Sotiropoulou G, Agelaki S, Pantel K.

Breast Cancer Res. 2010;12(4):307. doi: 10.1186/bcr2601. Epub 2010 Jul 23.

47.

Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V.

Anticancer Res. 2010 Jul;30(7):3031-8.

PMID:
20683051
48.

PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.

Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES.

J Mol Diagn. 2010 Sep;12(5):697-704. doi: 10.2353/jmoldx.2010.100008. Epub 2010 Jul 8. Erratum in: J Mol Diagn. 2013 Sep;15(5):730.

49.

Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group.

Agelaki S, Hatzidaki D, Kotsakis A, Papakotoulas P, Polyzos A, Ziras N, Gioulbasanis I, Karampeazis A, Agelidou A, Tsiafaki X, Chandrinos V, Lerikou M, Georgoulias V.

Oncology. 2010;78(3-4):229-36. doi: 10.1159/000315729. Epub 2010 Jun 4.

PMID:
20523083
50.

Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S.

Breast Cancer Res. 2009;11(6):R84. doi: 10.1186/bcr2452. Epub 2009 Nov 17.

Supplemental Content

Loading ...
Support Center